Compositions and methods for treating cancer with anti-CD33 immunotherapy
AssigneesLentigen Technology, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsRimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
Life of this patent
Estimating the term…
Abstract
Chimeric antigen receptors containing CD33 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
Claims13
A method of providing an anti-tumor immunity in a human subject comprising administering to the human subject an effective amount of an isolated T cell or an isolated natural killer (NK) cell, wherein the isolated T cell or the isolated NK cell comprise a vector comprising a nucleic acid molecule encoding a chimeric antigen receptor (CAR) comprising, from N-terminus to C-terminus:
- (i) at least one extracellular antigen binding domain that binds to CD33 comprising a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO:
- 4 or a single chain fragment variable (ScFv) domain selected from the group consisting of SEQ ID NO:
- 6, 8, 10 and 12;
- (ii) a transmembrane domain comprising a transmembrane domain of a protein selected from the group consisting of the T-cell receptor (TCR) alpha chain, the TCR beta chain, the TCR zeta chain, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154, or any combination thereof;
- (iii) at least one costimulatory domain comprising a functional signaling domain selected from the group consisting of OX40, CD70, CD27, CD28, CD5, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), DAP10, DAP12, and 4-1BB (CD137), or any combination thereof;
- and
- (iv) an intracellular signaling domain comprising a signaling domain selected from the group consisting of a 4-1BB (CD137);
- CD28, and CD3 zeta signaling domain, or a combination thereof, thereby providing anti-tumor immunity to the human subject,
- wherein the human subject has at least one tumor that expresses CD33.
A method of treating cancer in a human subject, comprising administering to the human subject an effective amount of an isolated T cell or an isolated NK cell, wherein the isolated T cell or the isolated NK cell comprise a vector comprising a nucleic acid molecule encoding a CAR comprising, from N-terminus to C-terminus:
- (i) at least one extracellular antigen binding domain that binds to CD33 comprising a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO:
- 4 or a single chain fragment variable (ScFv) domain selected from the group consisting of SEQ ID NO:
- 6, 8, 10 and 12;
- (ii) a transmembrane domain comprising a transmembrane domain of a protein selected from the group consisting of the T-cell receptor (TCR) alpha chain, the TCR betachain, the TCR zeta chain, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154, or any combination thereof;
- (iii) at least one costimulatory domain comprising a functional signaling domain selected from the group consisting of OX40, CD70, CD27, CD28, CD5, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), DAP10, DAP12, and 4-1BB (CD137), or any combination thereof;
- and
- (iv) an intracellular signaling domain comprising a signaling domain selected from the group consisting of a 4-1BB (CD137);
- CD28, and CD3 zeta signaling domain, or a combination thereof, in an amount effective to treat cancer in the human subject,
- wherein the human subject has been diagnosed with a cancer expressing CD33.
Dependencies are inferred from the claim text.